Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
NVIDIA (NVDA.US) joins forces with Goldman Sachs, Blackstone, and other Wall Street financial giants to plan a $500 billion AI financing initiative, providing funds for clients to purchase chips.

NVIDIA (NVDA.US) joins forces with Goldman Sachs, Blackstone, and other Wall Street financial giants to plan a $500 billion AI financing initiative, providing funds for clients to purchase chips.

智通财经智通财经2026/08/14 23:16
Show original
JitTong Finance APP has learned that NVIDIA (NVDA.US) is teaming up with Goldman Sachs (GS.US), Blackstone Group (BX.US), Apollo Global Management (APO.US), and other major Wall Street financial institutions to plan an AI computing power financing program worth up to 500 billion US dollars. The aim is to help clients such as OpenAI and Anthropic obtain the huge capital needed to purchase NVIDIA chips, thus providing new financing channels for future AI infrastructure expansion.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds